ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Chronic myeloid leukemia (CML) resistance to BCR-ABL tyrosine kinase inhibitors can arise from ABL kinase domain mutations, BCR-ABL fusion gene amplification, or kinase-independent mechanisms.